Dr. David Eberhard joins Flagship as Chief Medical Pathologist

Pharmaceutical veteran anatomic pathologist strengthens Flagship’s expertise in oncology and clinical trials

Flagstaff, AZ (04/26/2011) —Flagship Biosciences announced today that Dr. David Eberhard MD, PhD has been appointed Chief Medical Pathologist. Dr. Eberhard is an anatomic/molecular pathologist highly regarded for his leadership and expertise in oncology clinical trials and pharmaceutical drug development. He holds an academic appointment as Associate Professor, Department of Pathology and the Lineberger Comprehensive Cancer Center, at the University of North Carolina at Chapel Hill. Previously, he served as the Director of Clinical Trials Pathology Services at LabCorp’s Center for Molecular Biology and Pathology, after a distinguished career at Genentech and as an industry consultant. He earned his MD in Pathology and his Ph.D. in pharmacology from the University of Michigan Medical School, followed by residency training in anatomic pathology and neuropathology at the University of Virginia School of Medicine.

Dr. Eberhard has been active in developing standardized approaches for molecular pathologic analyses of solid tumors in clinical trials, such as the publication of industry working group recommendations for EGFR testing in pathology. “The addition of Dr. Eberhard to Flagship’s pathology and development team further strengthens our position as a leader in qualitative and quantitative digital pathology.” said Dr. David Young, President of Flagship Biosciences.“He has been a steady encouragement from the beginnings of Flagship and has a great vision for applications of image analysis in both research and clinical medicine”.

David Eberhard has served on the Scientific Advisory Board for Flagship Biosciences, and in his new expanded role will strengthen the collaboration provided by Flagship’s network of anatomic pathologists of various specializations in the United States and Europe, and facilitate closer interactions and innovation between Flagship’s new quantitative pathology approaches, academic investigation and oncology drug development. “Flagship has a unique focus on cutting-edge digital pathology approaches to maximize efficiency of anatomic pathology analyses, to allow precise, accurate and reproducible quantitation of pathology readouts, and to support the clinical development of drugs and companion diagnostics” said Dr. Eberhard. “Flagship’s perspective and expertise represent a valuable resource for basic, translational and clinical R&D that has huge potential to create real progress in science and industry.”

Flagship Biosciences is a pathologist-owned pharmaceutical services organization that specializes in the delivery of quantitative pathology to pharmaceutical, biotech, and medical device clients. Flagship leverages digital pathology to combine novel quantitative scoring algorithms with anatomic pathology expertise and experience. They are the largest provider of pathologist-supervised brightfield and fluorescence scanning and image analysis capabilities.